Powering Precision Health
with InformedDNA
We empower health organizations, research institutions, and diagnostic providers with cutting-edge pharmacogenomics (PGx) testing and infectious disease molecular diagnostics. Backed by decades of scientific expertise and curated genomic literature, we provide scientifically-rigorous and informative reports designed, to enhance diagnostic accuracy and support effective therapeutic decision-making.
Leveraging sophisticated algorithms, our PGx solution analyzes clinical laboratory pharmacogenomic results to interpret how an individual’s unique genetic makeup influences their response to medications, in concert with other medication-associated risks. This empowers your clients to tailor prescribing for improved safety and efficacy, potentially reducing adverse drug reactions and treatment waste.
Recommendations for, and against, specific ADHD medications based on the patient’s DNA.
Comprehensive analysis of risks associated with polypharmacy in the cardiac patient include drug-drug interactions, anticholinergic burden, age- and pregnancy-related concerns, FDA warnings, food and drink interactions, and genetics.
Based on an individual’s pharmacogenomics profile, this report provides details for the treatment of depression, anxiety, ADHD, and other psychiatric health concerns.
Addressing clinical pain management, CLS tackles medication safety, efficacy, and Opioid Use Disorder predilection in an actionable report that determines the most appropriate pain medication based on an individual’s DNA.
Includes interpretation of semi-quantitative laboratory assays of pathogenic microorganisms and, in concert with antibiotic resistance testing, provides antibiotic treatment options.
Enhances diagnostic accuracy and supports effective therapeutic decision-making for conditions such as gastroenteritis, food poisoning, and other GI-related ailments.
Provides identification of pathogenic organisms to guide rapid therapeutic decisions.
Diagnoses multiple respiratory ailments including SARS, pneumonia, and TB from a single sample.
Provides detailed infection confirmation to guide rapid therapeutic decisions.
Gain access to the foundational insights required to drive personalized healthcare, optimize patient outcomes, and contribute to a healthier world.
All guidance is transparent and cited with the published literature references available for independent review. The literature research analysis also makes clear that the state of knowledge in pharmacogenomics is not fixed. New literature that refines previously published guidance, or provides wholly new guidance, is published continually. Researchers and other users who utilize PGx reference information, including any meta-analysis information generated by RAISE, should do so with the full knowledge of these limitations.
1. The Coriell Personalized Medicine Collaborative Pharmacogenomics Appraisal, Evidence Scoring and Interpretation System, Genome Medicine, October 2013. Gharani, N; Keller, MA; Stack, CB; Hodges, LM; Schmidlen, TJ; Lynch, DE; Gordon, ES; Christman, MF.
2. Diagnosing Bacterial Vaginosis with a Novel, Clinically-Actionable Molecular Diagnostic Tool. J Appl Microb Res. Vol: 1, Issue: 2 (01-08). Jarvis JP, Rains D, Kradel SJ, Elliott J, Diamond EE, Avaniss-Aghajani E, Yasharpour F, Shaman JA (2018)
Labs of all sizes are utilizing RAISE to improve lives, reduce costs, and increase revenue. Ready to join them?
